Human well-being medicine has exploded!

At the beginning of 2022, the new drug research and development of Renfu Medicine has ushered in good news one after another.
The improved new drug RF16001 for postoperative analgesia and the 1.
1 class new drug Bairesi Pill for the treatment of stable vitiligo have been approved for clinical use.
The Phase III clinical trials of recombinant plasmid-hepatocyte growth factor injection, a high-profile biological drug Class 1 new drug, are progressing normally, and Renfu Medicine is expected to win Class 1 new drugs in the three major fields of chemical medicine, traditional Chinese medicine and biological medicine
.

Looking back on 2021, what good achievements have Renfu achieved? What explosion models will be launched in 2022? Let's look down

Class 1 new drugs of chemical drugs broke out, and new drugs of traditional Chinese medicine sprinted to the market

Class 1 new drugs of chemical drugs broke out, and new drugs of traditional Chinese medicine sprinted to the market

Renfu Medicine's Class 1 new drug remazolam besylate for injection, approved for marketing in 2020, has successfully entered the 2021 edition of the National Medical Insurance Negotiation Catalogue, and its use is limited to sedation for colonoscopy
.

Renfu Medicine stated that the sales of the new drug in 2020 will be about 10 million yuan, and it will rise to 40 million yuan in the first three quarters of 2021.

In 2021, Renfu Medicine will have another class of new drugs approved for marketing.
The indication of fospropofol disodium for injection is induction of general anesthesia.
We will wait and see whether this year's medical insurance negotiation will beckon to it
.

In addition, the company's new class 1 drug HW021199 for the treatment of idiopathic pulmonary fibrosis (IPF) was also approved for clinical use last year, and Phase I clinical trials are in progress

Table 1: Category 1 new drugs that have been approved for clinical use or reported for production and are under review since 2017

Source: MED2.
0 China Drug Evaluation Database

The total flavonoid capsules of Guangjincao of Renfu Medicine are 1.
2 new drugs of traditional Chinese medicine.
This medicine adopts modern advanced technology to purify traditional Chinese medicine.
Macroporous adsorption resin purification technology is used in the single-flavor Chinese medicinal material of "Guangjincao" to separate and purify the Guangjincao.
The total flavonoids are researched and developed into traditional Chinese medicine preparations based on the effective parts, which are mainly used for the prevention and treatment of urinary tract calculi
.

The new drug is expected to become the first class 1 new drug in the traditional Chinese medicine market for urinary system diseases, and will also become the first class 1 new drug of traditional Chinese medicine of Renfu Medicine

On January 13, 2022, Renfu Pharmaceutical announced that the company's second new class 1 traditional Chinese medicine drug was approved for clinical use
.

It is reported that Bairesi Pill is derived from the hospital preparations contained in the "Preparation Standards for Uyghur Medical and Medical Institutions in Xinjiang Uygur Autonomous Region"

The first new class 1 biological drug is on the way, and new improved drugs have accumulated

The first new class 1 biological drug is on the way, and new improved drugs have accumulated

Figure 1: Clinical progress of recombinant plasmid-hepatocyte growth factor injection

Source: Minet China Drug Clinical Trials Publicity Library

On January 5, 2022, the company stated in response to investors' questions that the company's research and development project of the recombinant plasmid-hepatocyte growth factor injection, a new class 1 biological drug, is currently in the phase III clinical trial stage, and the indication is severe lower extremity ischemia.
Pain at rest in an extremity due to disease
.

The new drug is China's first plasmid DNA drug to enter clinical trials, representing the advanced level of gene therapy drug development in China

Renfu Medicine is not only deeply engaged in the field of chemical medicine, but also Chinese medicine and biological medicine are about to usher in the first class 1 new medicine
.

In addition, the upsurge of new improved chemical drugs has swept China in recent years.

Table 2: Class 2 new drugs (excluding new indications) declared for clinical trials by Renfu Medicine in 2021

Source: MED2.
0 China Drug Evaluation Database

At present, the company's dexmedetomidine transdermal patch has the fastest progress and has entered Phase I clinical trials, together with the clinically approved RF16001 for injection, paracetamol and hydrocodone sustained-release tablets, and dexmedetomidine which is under review and approval Detomidine Transdermal Patch (II), Dexmedetomidine Hydrochloride Nasal Spray, Paracetamol Oxycodone Sustained-Release Tablets, all 6 products are analgesic drugs.
It can be seen that Renfu Medicine has priority in the research and development of improved new drugs.
It is worth continuing to observe whether it will expand to other fields in the future after choosing its own strong field
.

Reasonable layout of generic drug echelon, 5 blockbuster first imitations are coming soon

Reasonable layout of generic drug echelon, 5 blockbuster first imitations are coming soon

The innovative drugs of Renfu Medicine are extending from chemical drugs to the fields of traditional Chinese medicine and biological drugs, and the echelon of generic drugs is also being rationally deployed
.

In 2021, the number of generic drugs approved for listing by Renfu Medicine is not large, only 4, of which 2 are the first generic + the first review, and 1 is the first review, all of which are high-quality generic drugs

Table 3: Generic drugs approved for listing by Renfu in 2021

Source: MED2.
0 China Drug Evaluation Database

Midazolam oral solution was negotiated into the 2021 version of the National Medical Insurance List, and its use is limited to sedation/anxiety/amnesia before and during diagnostic or therapeutic operations in children; it can also be used for preoperative sedation/anxiety in children /forget
.
Renfu Medicine stated that the company's first generic drug alfentanil hydrochloride injection approved in 2020 will also continue to strive for the next round of medical insurance negotiations
.

According to the data on the NMPA official website, on January 7, 2022, the 4 types of generic entecavir tablets of Renfu Medicine were approved for listing, and the company officially entered the market, which is a large variety of over 1 billion.
What blockbuster generic drugs will be launched next?

Table 4: Generic drugs reported for production and under review by Renfu since 2020

Source: MED2.
0 China Drug Evaluation Database

Since 2020, there are 16 generic drugs that Renfu Pharmaceutical has reported for production and are under review, of which 5 products are expected to hit the first generic drugs
.
Tofacitinib Citrate Sustained-Release Tablets, Sugammadex Sodium Sodium Injection, and Oxycodone Hydrochloride Sustained-Release Tablets will have a combined sales scale of over 100 million yuan in 2020 at terminals in Chinese public medical institutions and physical pharmacies in Chinese cities
.

Total sales volume of Febuxostat Tablets, Metoprolol Succinate Extended-Release Tablets, Finasteride Tablets, Propofol Medium/Long Chain Fat Emulsion Injection in Chinese public medical institutions and Chinese urban physical pharmacies in 2020 Over 1 billion yuan
.
As the first-tier pharmaceutical company in China, Renfu Pharmaceutical will also participate in the market competition of these large varieties and gain a share of the pie by virtue of its brand strength
.

When it comes to generic drugs, centralized procurement has become an inevitable storm
.
Up to now, Renfu Medicine and its subsidiaries have reviewed/deemed 38 products, including acetaminophen tablets, clindamycin hydrochloride capsules, vitamin B6 tablets, ibuprofen tablets, gliclazide The release tablets and misoprostol tablets have successfully won the bids for the second to fifth batches of national procurement
.
With the special implementation of the sixth batch of insulin, the seventh batch of national procurement is just around the corner .

Table 5: Changes in the market share of the products that Renfu won the bid of Guocai

Source: Minet.
com China's public medical institutions terminal competition pattern

There are 21 products that Renfu Medicine has reviewed and have not been included in the national procurement, among which the exclusive review includes Metoprolol Tartrate Injection, Levobupivacaine Hydrochloride Injection, Naproxen Sodium Tablets, Mida Zolam oral solution, fentanyl citrate injection and hydromorphone hydrochloride injection 6 products
.

Table 6: Products that have been reviewed by Renfu Medicine and have not been included in the national procurement (number of companies that have been reviewed ≥ 3)

Source: Minet.
com China's public medical institutions terminal competition pattern

Note: sales below 100 million yuan are indicated by *

There are 6 products that have been reviewed by more than 3 companies, and Renfu Medicine has been reviewed according to supplementary applications
.
Omeprazole Sodium for Injection is a large variety with a value of over 4 billion, and more than 20 companies have been evaluated.
The competition for centralized procurement is extremely high, and Renfu Medicine’s market share is less than 1%; compound sulfamethoxazole tablets and The number of companies that have reviewed vitamin B2 tablets has also reached 6 or 5.
Renfu Medicine is the TOP2 company of compound sulfamethoxazole tablets, and the share of vitamin B2 tablets is not high
.

Judging from the products that Renfu Medicine has won the bid for Guocai earlier, 4 products have achieved a substantial increase in the market share of public medical institutions in China after winning the bid.
The wind of centralized procurement has reversed the market situation
.

Epilogue

Epilogue

At present, China's innovative drug market is gradually becoming stronger, and new policy dividends have been introduced at the national level to encourage innovation.
As a leading pharmaceutical company, Renfu Medicine is also accelerating its transformation
.
It is reported that the company currently has more than 200 products under development, of which there are more than 20 Class 1 new drugs under development, 24 projects are listed as major national new drug creation projects, and 2 projects have been approved by the National Highest Technology Research and Development Program (863 Program).
, As the research products gradually realize the transformation of achievements, the company will continue to strengthen its own strength in the fierce market competition and strive for more brilliant achievements
.